SS Innovations International Inc. (NASDAQ: SSII) announced record first-quarter 2026 financial results, with revenue surging 116.8% year over year to $11.1 million, driven by increased installations of its SSi Mantra surgical robotic system and higher procedure volumes. The company reported a gross profit of $5.3 million, up from $1.1 million in the same period last year, reflecting the scaling of its commercial operations.
As of the end of Q1 2026, the installed base of SSi Mantra systems reached 194 across 11 countries, with nearly 9,750 cumulative robotic procedures completed. The company has since updated that as of June 22, 2026, the cumulative number of multi-specialty procedures has grown to 11,719, including 612 cardiac procedures, 175 telesurgeries, and 212 pediatric surgeries. Approximately 2,100 physicians have been trained on the SSi Mantra, which has been used to perform over 170 different types of procedures.
During the quarter, SS Innovations received regulatory approvals in Sri Lanka, Kenya, Indonesia, and the Philippines, expanding its international market access. The company also completed what it describes as the world's longest-distance robotic cardiac telesurgery, demonstrating the capabilities of its remote surgery platform. This milestone underscores the potential for telesurgery to bridge healthcare gaps in underserved regions.
The company continues to pursue regulatory clearance in both the United States and Europe, which would open significant markets and further accelerate adoption. SS Innovations is also expanding its presence in emerging healthcare markets, where demand for minimally invasive surgical technologies is growing rapidly.
The strong Q1 results reflect increasing confidence in the SSi Mantra system among healthcare providers. The platform's multi-specialty capabilities, including cardiac, pediatric, and telesurgery, position it as a versatile tool for hospitals seeking to enhance surgical outcomes and expand access to care. As the company scales its training programs and secures additional regulatory approvals, it is poised to capture a larger share of the global surgical robotics market.
For more information, visit the company's website at SSInnovations.com. This story is based on a press release distributed by InvestorWire, a specialized communications platform. For details on terms and disclaimers, refer to the InvestorWire disclaimer.
